These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 15359943)

  • 21. Drotrecogin alfa (activated) in patients with severe sepsis and a high risk of death.
    Friedrich JO; Adhikari NK; Meade MO
    Crit Care; 2006; 10(6):427. PubMed ID: 17214908
    [No Abstract]   [Full Text] [Related]  

  • 22. Treatment of severe sepsis with Xigris: implications for the clinical nurse specialist.
    Powers J; Jacobi J
    Clin Nurse Spec; 2003 May; 17(3):128-30. PubMed ID: 12792186
    [No Abstract]   [Full Text] [Related]  

  • 23. [Questionable efficacy and safety of activated drotrecogin alpha (activated protein C) in the treatment of severe sepsis].
    Girbes AR; Polderman KH; Beishuizen A; van Zanten AR; Schultz MJ
    Ned Tijdschr Geneeskd; 2006 Jun; 150(22):1265-6; author reply 1266. PubMed ID: 16796179
    [No Abstract]   [Full Text] [Related]  

  • 24. Drotrecogin alfa (activated) administration: too many subgroups.
    Carlet J
    Crit Care Med; 2003 Oct; 31(10):2564; author reply 2564-5. PubMed ID: 14530774
    [No Abstract]   [Full Text] [Related]  

  • 25. Targeting the coagulation cascade in sepsis: did we find the "magic bullet"?
    Mathiak G; Neville LF; Grass G
    Crit Care Med; 2003 Jan; 31(1):310-1. PubMed ID: 12545036
    [No Abstract]   [Full Text] [Related]  

  • 26. Can we RESOLVE the treatment of sepsis?
    Opal SM
    Lancet; 2007 Mar; 369(9564):803-804. PubMed ID: 17350431
    [No Abstract]   [Full Text] [Related]  

  • 27. Criteria for use of drotrecogin alfa.
    Jacobi J
    Am J Health Syst Pharm; 2004 Jan; 61(2):203-4; author reply 204-5. PubMed ID: 14750407
    [No Abstract]   [Full Text] [Related]  

  • 28. [Is there a place for activated protein C (Xigris) in the treatment of severe imported malaria in the adult?].
    Nau A; Peytel E; Petrognani R
    Ann Fr Anesth Reanim; 2006 Oct; 25(10):1085-6. PubMed ID: 17005364
    [No Abstract]   [Full Text] [Related]  

  • 29. Recombinant human activated protein C sentenced to the death of a thousand cuts?
    O'Brien JM
    Crit Care Med; 2007 Jun; 35(6):1609-10. PubMed ID: 17522532
    [No Abstract]   [Full Text] [Related]  

  • 30. [Treatment of severe sepsis and multiple organ failure with activated protein C].
    Strøm JJ
    Ugeskr Laeger; 2004 Mar; 166(11):995. PubMed ID: 15049233
    [No Abstract]   [Full Text] [Related]  

  • 31. Severe sepsis and the role of novel therapeutic agents. Position statement of the Critical Care Society of South Africa on severe sepsis and the role of novel therapeutic agents such as drotrecogin alfa (activated).
    Critical Care Society of South Africa Working Group
    S Afr Med J; 2003 Jun; 93(6):416-7. PubMed ID: 12916374
    [No Abstract]   [Full Text] [Related]  

  • 32. New mode of intervention in sepsis treatment.
    Foubister V
    Drug Discov Today; 2003 Jul; 8(14):610-2. PubMed ID: 12867140
    [No Abstract]   [Full Text] [Related]  

  • 33. The use of drotrecogin alfa recombinant activated protein C for severe sepsis in the critically burned patient: a new treatment approach.
    Weintraub J; Satterwhite T; Allo M
    Burns; 2006 Sep; 32(6):783-7. PubMed ID: 16879921
    [No Abstract]   [Full Text] [Related]  

  • 34. Severe sepsis and therapy with activated protein C.
    Parrillo JE
    N Engl J Med; 2005 Sep; 353(13):1398-400. PubMed ID: 16192486
    [No Abstract]   [Full Text] [Related]  

  • 35. [Sepsis in the surgical setting: indication for activated C protein].
    Payen DM; Matéo J
    Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():40-2. PubMed ID: 15359942
    [No Abstract]   [Full Text] [Related]  

  • 36. The efficacy of drotrecogin alfa depends on severity of illness.
    Deans KJ; Minneci PC; Eichacker PQ; Natanson C
    Crit Care Med; 2004 Nov; 32(11):2347. PubMed ID: 15640655
    [No Abstract]   [Full Text] [Related]  

  • 37. [Can we still afford progress in intensive care medicine? Re: the article from DMW 1-2/2004].
    Rustige J
    Dtsch Med Wochenschr; 2004 Jul; 129(31-32):1698; author reply 1699-70. PubMed ID: 15273923
    [No Abstract]   [Full Text] [Related]  

  • 38. A new weapon against severe sepsis related to necrotizing fasciitis.
    Purnell D; Hazlett T; Alexander SL
    Dimens Crit Care Nurs; 2004; 23(1):18-23. PubMed ID: 14734896
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Meeting unmet needs in patients with sepsis: the role of drotrecogin alfa (activated).
    McEvoy M
    Am J Crit Care; 2003 Sep; 12(5):398; author reply 398. PubMed ID: 14503421
    [No Abstract]   [Full Text] [Related]  

  • 40. [Use of recombinant human activated protein C in severe sepsis in patient with a pericardial hemorrhagic collection after a recent cardiac surgery].
    Fournet X; Dubernet-Gaudiot P; Treilhaud M; Blanloeil Y
    Ann Fr Anesth Reanim; 2005 Apr; 24(4):435-6. PubMed ID: 15826797
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.